WRF Capital

Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers to continue their research work and discover drugs. It was founded in 2016 and is headquartered in Seattle, Washington.

AdaptX is a healthcare data analytics and AI company that specializes in enhancing clinical and workflow outcomes for hospitals and surgery centers. Founded in Seattle in 2016 as a spin-off from Seattle Children's Hospital, AdaptX provides a platform that enables medical leaders and clinicians to access and analyze clinical data effectively. The platform integrates algorithms with existing electronic data systems, allowing healthcare providers to monitor performance, compare treatment approaches, and define patient cohorts. Through automated analytics, AdaptX helps healthcare service providers improve the quality and safety of care while also reducing costs.

Somalytics commercializes miniature sensors for eye tracking, human-machine interface, wearables, and industrial safety. It’s the world’s first paper-composite capacitive sensor. It’s paper-thin, consumes little power, and can potentially be disposable. The company was founded in 2021 and is based in Seattle, Washington.

ThruWave produces millimeter wave imaging technology designed for markets including robotics, construction, and quality control. The company's low-cost sensors for commercial and industrial applications use patent-pending radar signal processing innovations and GPU accelerated image reconstruction techniques. Its technology lowers risk by imaging the internal structure of walls, ceilings, and floors that enable construction professionals to work faster. ThruWave was founded in 2017 and is headquartered in Seattle, Washington.

Membrion, Inc., founded in 2016 and based in Seattle, Washington, specializes in the manufacturing and commercialization of advanced membranes that filter molecules, including ions, under a variety of conditions such as heat, acidity, and biological sensitivity. Originating as a spin-out from the University of Washington, Membrion has received funding from multiple organizations, including the National Science Foundation and private investors, which has facilitated the transition from research to commercial production. The company's innovative ion exchange membrane technology is designed for applications in flow batteries, water purification, fuel cells, and pharmaceuticals, offering clients membranes that feature a longer lifespan and reduced costs.

AnswerDash, Inc. is a Seattle-based company that offers a cloud-based Q&A platform designed to provide contextual answers to customers on websites, web applications, and mobile experiences. Founded in 2012 and originally known as Qazzow, Inc., the company allows businesses to integrate self-service features that enable customers to obtain answers through a point-and-click interface, facilitating easy access to information without cluttering web pages. By predicting user questions based on the content of the page, AnswerDash helps reduce support costs and enhances customer engagement. The platform can also integrate with live chat services to offer personalized assistance. As of June 2020, AnswerDash operates as a subsidiary of CloudEngage, Inc.

FlexMinder, Inc. is a Seattle-based company that develops enterprise software solutions aimed at private health exchanges, health carriers, and third-party administrators (TPAs). Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, enhancing the management of medical spending for flexible spending accounts. The company aggregates healthcare information from various sources to streamline claims submission, significantly reducing manual processing time and costs for TPAs. By providing online tools for managing the reimbursement process, FlexMinder aims to improve the user experience for consumers utilizing their flexible spending arrangements. In 2013, the company secured $1.4 million in Series AA financing to support its growth initiatives and was selected for the TechStars incubator program. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

SNUPI Technologies, Inc. is a Seattle-based company specializing in sensor technology and services aimed at enhancing home safety, security, and loss prevention. Founded in 2012, the company developed a wireless sensing solution called WallyHome, which monitors critical environmental factors such as moisture, temperature, and humidity. This system is designed to detect water leaks and other hazards, alerting homeowners to potential issues before they escalate, including risks related to mold and humidity. SNUPI Technologies leverages existing electrical wiring in homes to create a comprehensive sensing platform, facilitating effective communication and notifications through its web service.

Modumetal, Inc. is a manufacturer and developer of nano laminated metals and materials, founded in 2006 and headquartered in Seattle, Washington, with an additional sales office in The Woodlands, Texas. The company specializes in producing industrial-scale nanolaminated alloys that are stronger and lighter than steel, as well as more corrosion-resistant and durable than traditional metals. By utilizing electricity instead of heat in their manufacturing process, Modumetal reduces environmental impact while delivering high-performance solutions. Their products, which include customized alloys, coatings, fasteners, pumps, valves, and production tubulars, cater to various industries, including energy, aerospace, automotive, defense, infrastructure, and construction. Modumetal's technology enables these sectors to enhance performance and achieve cost-effective alternatives to conventional materials.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for a range of indications, including inflammation, complement-mediated diseases, and central nervous system disorders. The company is known for its commercial product, OMIDRIA, which is used during cataract surgery in the United States. Omeros has several clinical programs, with its lead candidate, Narsoplimab, in Phase III trials for conditions such as thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other clinical programs include OMS405 for opioid and nicotine addiction and OMS527 for addiction and compulsive disorders. The company also has a robust pipeline of preclinical programs targeting various disorders, including MASP-3 for paroxysmal nocturnal hemoglobinuria and a GPCR platform aimed at treating a broad range of diseases. Omeros was incorporated in 1994 and remains dedicated to addressing significant unmet medical needs.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.